By April 2020 , less than 3 organizations initiated Phase I-II safety and efficacy studies in human subjects for the COVID-19 vaccine .
The Coalition for Epidemic Preparedness Innovations ( CEPI ) – which is organizing a worldwide fund for rapid investment and development of vaccine candidates – indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021.By April 2020 , 115 vaccine candidates were in development , with four organizations having initiated Phase I-II safety and efficacy studies in human subjects .
COVID-19 vaccine